Nanjing Vazyme Biotech Co., Ltd (SHA:688105)

Market Cap	8.62B
Revenue (ttm)	1.34B
Net Income (ttm)	-29.64M
Shares Out	397.73M
EPS (ttm)	-0.09
PE Ratio	n/a
Forward PE	162.53
Dividend	0.30 (1.39%)
Ex-Dividend Date	n/a

Volume	1,041,462
Average Volume	2,629,624
Open	21.55
Previous Close	21.67
Day's Range	21.55 - 21.91
52-Week Range	19.58 - 26.77
Beta	0.89
RSI	56.39
Earnings Date	Apr 23, 2026

About Nanjing Vazyme Biotech

Nanjing Vazyme Biotech Co., Ltd offers technology solutions for life science, biomedicine, and in vitro diagnostics. The company offers nucleic acid extraction reagents, including DNA extraction, RNA extraction, microbiome nucleic acid extraction, sample treatment, and high-throughput automated extraction; molecular biology reagents comprising PCR, cloning/mutagenesis, reverse transcription, real-time PCR (qPCR), one-step RT-PCR/RT-qPCR, nucleic acid electrophoresis, genome editing techniques, isothermal amplification, and instant granules; and...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Employees: 2,754
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688105

Financial Performance

In 2024, Nanjing Vazyme Biotech's revenue was 1.38 billion, an increase of 7.15% compared to the previous year's 1.29 billion. Losses were -18.09 million, -74.50% less than in 2023.